Cairn Therapeutics
Thursday, June 06, 2024
Company Presentation
![Oncology](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_Oncology_MTC.png)
Company Presentation Theater 1
Cairn Therapeutics, Inc. is a pharmaceutical company with a mission to help patients beat cancer. Founded in 2016, Cairn is developing its lead candidate, CT-262, a first-in-its-class treatment for a broad array of solid and hematological tumors. Cairn holds the exclusive worldwide license to CT-262, which was invented at Scripps Research Institute using unique medicinal chemistry to create a highly potent agent that preferentially activates in cancer cells. In vitro and in vivo animal oncology studies have shown CT-262 to produce markedly better efficacy and surprisingly low toxicological effects compared to current first-line therapies in these nonclinical models.
v
![Cairn Therapeutics](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1819157-1-JPG.png)
Company Website:
http://www.cairntherapeutics.com
Lead Product in Development:
CT-262
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Company HQ City
Greenville
Company HQ State
DE
Company HQ Country
United States
CEO/Top Company Official
Scott Evangelista
Development Phase of Primary Product
Pre-Clinical
Primary Speaker